JPWO2022155530A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022155530A5 JPWO2022155530A5 JP2023543035A JP2023543035A JPWO2022155530A5 JP WO2022155530 A5 JPWO2022155530 A5 JP WO2022155530A5 JP 2023543035 A JP2023543035 A JP 2023543035A JP 2023543035 A JP2023543035 A JP 2023543035A JP WO2022155530 A5 JPWO2022155530 A5 JP WO2022155530A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- protein
- cov
- sars
- reading frame
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims 15
- 108700026244 Open Reading Frames Proteins 0.000 claims 9
- 150000002632 lipids Chemical class 0.000 claims 8
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims 7
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 4
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 3
- 102100031673 Corneodesmosin Human genes 0.000 claims 3
- 101710139375 Corneodesmosin Proteins 0.000 claims 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 3
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 3
- 229960005305 adenosine Drugs 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 3
- 229940029575 guanosine Drugs 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 239000002777 nucleoside Substances 0.000 claims 3
- 125000003835 nucleoside group Chemical group 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229920002477 rna polymer Polymers 0.000 claims 3
- 241001678559 COVID-19 virus Species 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- -1 amino lipid Chemical class 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- JFBCSFJKETUREV-LJAQVGFWSA-N 1,2-ditetradecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-LJAQVGFWSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163138228P | 2021-01-15 | 2021-01-15 | |
| US63/138,228 | 2021-01-15 | ||
| US202163140920P | 2021-01-24 | 2021-01-24 | |
| US63/140,920 | 2021-01-24 | ||
| US202163161433P | 2021-03-15 | 2021-03-15 | |
| US63/161,433 | 2021-03-15 | ||
| US202163173979P | 2021-04-12 | 2021-04-12 | |
| US63/173,979 | 2021-04-12 | ||
| US202163193547P | 2021-05-26 | 2021-05-26 | |
| US63/193,547 | 2021-05-26 | ||
| US202163222925P | 2021-07-16 | 2021-07-16 | |
| US63/222,925 | 2021-07-16 | ||
| US202163241963P | 2021-09-08 | 2021-09-08 | |
| US63/241,963 | 2021-09-08 | ||
| US202163283905P | 2021-11-29 | 2021-11-29 | |
| US63/283,905 | 2021-11-29 | ||
| US202163284570P | 2021-11-30 | 2021-11-30 | |
| US63/284,570 | 2021-11-30 | ||
| PCT/US2022/012614 WO2022155530A1 (en) | 2021-01-15 | 2022-01-14 | Variant strain-based coronavirus vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503699A JP2024503699A (ja) | 2024-01-26 |
| JPWO2022155530A5 true JPWO2022155530A5 (https=) | 2025-04-14 |
| JP2024503699A5 JP2024503699A5 (https=) | 2025-04-14 |
Family
ID=80168090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543035A Pending JP2024503699A (ja) | 2021-01-15 | 2022-01-14 | バリアント株ベースのコロナウイルスワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20240139309A1 (https=) |
| EP (1) | EP4277653A1 (https=) |
| JP (1) | JP2024503699A (https=) |
| AU (1) | AU2022207495A1 (https=) |
| CA (1) | CA3208303A1 (https=) |
| WO (1) | WO2022155530A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| TWI844087B (zh) * | 2021-09-02 | 2024-06-01 | 高端疫苗生物製劑股份有限公司 | 抗新型冠狀病毒(SARS-CoV-2)變異株之免疫組合物及方法 |
| US12397051B2 (en) * | 2021-09-14 | 2025-08-26 | Globe Biotech Limited | Vaccine for use against coronavirus and variants thereof |
| WO2023092069A1 (en) * | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| EP4577236A1 (en) * | 2022-08-22 | 2025-07-02 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccines against coronaviruses |
| WO2024050483A1 (en) * | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
| CN120548193A (zh) * | 2022-10-19 | 2025-08-26 | 嘉晨西海(杭州)生物技术有限公司 | 目的基因rna制剂 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| CN117567571A (zh) * | 2023-09-28 | 2024-02-20 | 上海蓝鹊生物医药有限公司 | 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8278063B2 (en) | 2007-06-29 | 2012-10-02 | Commonwealth Scientific And Industrial Research Organisation | Methods for degrading toxic compounds |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| WO2009075886A1 (en) | 2007-12-11 | 2009-06-18 | The Scripps Research Institute | Compositions and methods related to mrna translational enhancer elements |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| KR102399799B1 (ko) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | 인공 핵산 분자 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| US9259829B1 (en) | 2014-08-25 | 2016-02-16 | Cougar Holdings, Llc | Roofing and nail removal hammer |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| MX2022009460A (es) * | 2020-02-04 | 2022-12-16 | Curevac Ag | Vacuna contra el coronavirus. |
| IL297414A (en) * | 2020-04-22 | 2022-12-01 | Pfizer | Vaccine against the corona virus |
| CA3177940A1 (en) * | 2020-05-07 | 2021-11-11 | Anusha DIAS | Optimized nucleotide sequences encoding sars-cov-2 antigens |
-
2022
- 2022-01-14 JP JP2023543035A patent/JP2024503699A/ja active Pending
- 2022-01-14 AU AU2022207495A patent/AU2022207495A1/en not_active Abandoned
- 2022-01-14 WO PCT/US2022/012614 patent/WO2022155530A1/en not_active Ceased
- 2022-01-14 EP EP22702382.7A patent/EP4277653A1/en active Pending
- 2022-01-14 CA CA3208303A patent/CA3208303A1/en active Pending
- 2022-01-14 US US18/272,496 patent/US20240139309A1/en active Pending
-
2025
- 2025-08-08 US US19/294,594 patent/US20250367278A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022155530A5 (https=) | ||
| JPWO2021155243A5 (https=) | ||
| JPWO2022155524A5 (https=) | ||
| WO2019027999A1 (en) | BIOMIMETIC NANOMATERIALS AND USES THEREOF | |
| JP2023164537A5 (https=) | ||
| JP7702159B2 (ja) | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 | |
| JPWO2022221335A5 (https=) | ||
| JPWO2022221440A5 (https=) | ||
| CA2760776C (en) | Lipid compositions for the delivery of therapeutic agents | |
| JP7150608B6 (ja) | 多量体コード核酸及びその使用 | |
| JP2024099679A (ja) | 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質 | |
| AU2024201485A1 (en) | Modified oligonucleotides and methods of use | |
| EP3243504A1 (en) | Improved lipid formulation | |
| JP2022532213A (ja) | Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス | |
| CA3044134A1 (en) | Improved compositions and methods for the delivery of nucleic acids | |
| JPWO2021113777A5 (https=) | ||
| WO2009132131A1 (en) | Amino lipid based improved lipid formulation | |
| JP7789103B2 (ja) | 原発性線毛機能不全症の治療のための組成物および方法 | |
| JPWO2021116462A5 (https=) | ||
| Buonocore et al. | Expression in Escherchia coli and purification of sea bass (Dicentrarchus labrax) interleukin 1β, a possible immunoadjuvant in aquaculture | |
| JPWO2021096763A5 (https=) | ||
| JPWO2021251453A5 (https=) | ||
| JPWO2023091787A5 (https=) | ||
| Payette et al. | Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms | |
| JPWO2023091490A5 (https=) |